Akston, the Biotech Built for Pets, today announced results from a randomized head-to-head study evaluating AKS-548d and AKS-734, the company's NGF-targeting Ambifect® Fc-fusion immunotherapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results